Apellis cites current challenges with Syfovre launch but bright prospects in the long term
Fierce Pharma
FEBRUARY 28, 2024
On Tuesday, when Apellis presented its quarterly earnings, its report raised more questions about Syfovre than it answered. . | The first 12 months on the market for Apellis’ geographic atrophy (GA) drug Syfovre have been a rollercoaster ride. And there are still more loops to negotiate.
Let's personalize your content